Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dornase alfa - Genentech

Drug Profile

Dornase alfa - Genentech

Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNase

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
  • Class Antifibrotics; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase I/II Dry eyes; Graft-versus-host disease
  • Discontinued Chronic obstructive pulmonary disease; Lupus nephritis

Most Recent Events

  • 16 Oct 2019 University of Illinois and Genentech terminates a phase I/II trial in Dry eyes in USA due to slow accrual of patients(NCT02193490)
  • 24 Jun 2018 Biomarkers information updated
  • 06 Feb 2017 Dornase alfa is still in phase I/II trials for Dry eyes in USA (Ophthalmic, drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top